Heritage Wealth Advisors Reduces Stock Position in AbbVie Inc. $ABBV

Heritage Wealth Advisors decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 13.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,472 shares of the company’s stock after selling 1,010 shares during the period. Heritage Wealth Advisors’ holdings in AbbVie were worth $1,201,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. FF Advisors LLC lifted its holdings in AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after buying an additional 53 shares in the last quarter. Landaas & Co. WI ADV increased its position in shares of AbbVie by 1.1% during the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after acquiring an additional 53 shares during the period. Private Management Group Inc. raised its stake in shares of AbbVie by 1.9% during the first quarter. Private Management Group Inc. now owns 2,938 shares of the company’s stock valued at $616,000 after acquiring an additional 54 shares in the last quarter. LifeSteps Financial Inc. boosted its holdings in shares of AbbVie by 0.7% in the second quarter. LifeSteps Financial Inc. now owns 7,358 shares of the company’s stock valued at $1,366,000 after purchasing an additional 54 shares during the period. Finally, Silicon Valley Capital Partners grew its stake in AbbVie by 10.8% in the first quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock worth $118,000 after purchasing an additional 56 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV opened at $233.83 on Wednesday. The company has a market cap of $413.27 billion, a P/E ratio of 111.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The firm’s 50-day moving average price is $225.84 and its 200-day moving average price is $204.57. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the business earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 524.24%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ABBV shares. Piper Sandler restated an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Evercore ISI boosted their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective on the stock in a research note on Thursday, August 7th. Wells Fargo & Company lifted their price objective on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Finally, Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $240.14.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.